Javascript is not enabled.

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.

Skip to content
Content starts here


Leaving Website

You are now leaving and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.

VA to Cover New Alzheimer’s Drug Leqembi

Veterans with early stage of the disease will be eligible for treatment

The Department of Veterans Affairs has agreed to cover the drug lecanemab (brand name Leqembi) for some veterans with early-stage Alzheimer’s disease, Eisai Co. and Biogen Inc., the companies behind the drug, announced Monday.

spinner image boxes and vials of the drug leqembi
Eisai via AP

The VA will become the first major insurer to cover the treatment, which its makers say will cost $26,500 a year. It received accelerated approval from the U.S. Food and Drug Administration this year, becoming the second Alzheimer’s treatment to earn the status. Aduhelm, a similar drug, got accelerated approval in 2021.

According to an Eisai news release, “VHA (Veterans Health Administration) healthcare professionals meeting the criteria set forth by the VHA can prescribe Leqembi to veterans who fit the VHA’s criteria and the U.S. Food and Drug Administration’s current label.” The VA did not immediately respond to a request for comment.

Major insurers have not covered Leqembi or Aduhelm. In April 2022, the Centers for Medicare & Medicaid Services said it would restrict coverage of such monoclonal antibodies that had received accelerated FDA approval and targeted amyloid plaques for Alzheimer’s disease — a definition that covers the two drugs. Amyloid plaques are sticky clumps of protein that can disrupt brain cell function; researchers hypothesize that clearing them may slow the progression of Alzheimer’s. Medicare only covers these treatments for beneficiaries who are in approved clinical trials.

Eisai and Biogen say they continue to pursue FDA approval under the traditional drug approval pathway, a lengthier process that could open the door for wider acceptance from insurers and doctors. The Centers for Disease Control and Prevention estimates 14 million Americans will be affected by Alzheimer’s by 2060 if there is no successful intervention.

Discover AARP Members Only Access

Join AARP to Continue

Already a Member?